Response to: Â € Comment on â € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al

Yoshiya Tanaka, Koji Oba, Tsutomu Takeuchi

研究成果: Letter査読

ジャーナルAnnals of the rheumatic diseases
出版ステータスAccepted/In press - 2019

ASJC Scopus subject areas

  • 免疫アレルギー学
  • リウマチ学
  • 免疫学
  • 生化学、遺伝学、分子生物学(全般)